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Bovine live anthrax vaccineFoot-and-mouth disease (FMD) vaccination in Argentina is compulsory for most of the cattle population
and conducted by certiﬁed veterinarians. This organized campaign may facilitate the controlled applica-
tion of other vaccines against endemic diseases, provided immune responses against FMD are not hin-
dered. There is no published information on the interference of immunity against FMD vaccines when
applied together with a live bacterial vaccine. In this study we evaluated if the simultaneous application
of a Bacillus anthracis live vaccine with a commercial tetravalent oil-based FMD vaccine (FMD-vac) used
in Argentina, modiﬁes the antibody booster responses against FMD virus (FMDV) in cattle. Two groups of
16 heifers with comparable liquid phase blocking ELISA (LPBE) titers were immunized with the FMD-vac
alone or simultaneously with a commercial attenuated bovine anthrax Sterne strain vaccine (ABV). Serum
samples were obtained at 0, 25, 60 and 90 days post vaccination (dpv) and speciﬁc antibodies against two
FMDV vaccine strains were assessed by LPBE, avidity and IgG-isotype ELISAs. Bovines immunized
with FMD-vac or FMDV-V + ABV responded with a boost in the LPBE antibody titers and avidity at
25 dpv, and remained within similar levels up to the end of the study. Animals vaccinated with
FMD-vac + ABV had signiﬁcantly higher LPBE titers at 25 dpv, compared to those immunized with
FMD-vac alone; which was due to an increase in IgG2 titers. Overall, antibody titers elicited in both
groups were similar and followed comparable kinetics over time. We conclude that the simultaneous
application of a live anthrax vaccine with the current FMD tetravalent vaccine used in Argentina in cattle
previously immunized against FMD, did not counteract the serological response induced by FMD
vaccination.
 2015 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Foot and mouth disease (FMD) is a highly contagious acute
vesicular viral disease that affects cloven-hoofed animals. FMD
virus (FMDV) belongs to the genus Aphthovirus in the
Picornaviridae family, and includes seven serotypes: O, A, Asia, C,
and SAT-1, -2, and -3 [1]. The circulation of FMDV in susceptible
livestock imposes severe restrictions on the movement and trade
of animals and derived products, causing serious economic loss tothe affected countries [2]. FMD is endemic in many parts of Asia,
Africa, and South America, where vaccination of susceptible popu-
lations is widely used as a major control measure. Commercial for-
mulations usually contain more than one virus strain, as immune
responses induced by vaccination are strain-speciﬁc [3,4].
The vaccine currently used in Argentina is oil-adjuvanted and
contains four FMDV strains of latest regional circulation: O1/
Campos/Brazil/58 (O1/Campos), A24 Cruzeiro/Brazil/55 (A24/
Cruzeiro), A/Argentina/2001 (A/Arg/01) and C3/Indaial/Brazil/71
(C3/Indaial) [5,6]. FMD vaccination is compulsory and rigorously
controlled by the local sanitary authority (SENASA). SENASA pro-
vides the virus vaccine strains and vaccination is performed by
trained and certiﬁed personnel [7], animals are properly identiﬁed
and cold chain is veriﬁed and guaranteed. Vaccines are applied to
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schedules. Animals older than 2 years are immunized once a year,
while calves aged up to 2 years-old are vaccinated every 6 months.
Vaccine efﬁcacy as well as surveillance of vaccine immunity is per-
formed by serology. Strain-speciﬁc antibody titers obtained with
liquid phase blocking ELISA (LPBE) have been statistically corre-
lated to in vivo protection to assess vaccine potency and herd
immunity through the estimation of a percentage of expected pro-
tection (EPP) [8–12].
The controlled and correct application of vaccines is as impor-
tant as quality control assessments performed to the vaccine itself.
Vaccines may fail in inducing protection if cold chain is not pre-
served or if the vaccine is not properly applied. These side-issues
have major impact when working with livestock. However, gather-
ing all the animals, vaccinators and monitoring cold-chain is difﬁ-
cult to achieve, particularly in large regions, areas of difﬁcult access
or extensive production systems. In this scenario, the combination
or co-administration of vaccines together with the FMD vaccine
appears as a practical and efﬁcient option for immunizing live-
stock, as long as this practice does not interfere with the immuno-
genicity conferred by those vaccines applied.
One major pathogen affecting livestock, which also has zoonotic
impact, is Bacillus anthracis. B. anthracis is a Gram-positive bacillus
that forms spores that are highly resilient, surviving extremes of
temperature, low-nutrient environments, and harsh chemical
treatment. This bacterium is the etiologic agent of anthrax, an
endemic disease in many countries of Southern Europe, South
America, Asia and Africa [13]. In Argentina, livestock is concen-
trated in seven provinces in the center of the country, with 42 mil-
lion cows and nearly 2 million rural inhabitants which implies a
high risk for anthrax transmission [14]. A surveillance performed
in Buenos Aires Province, which represents 32% of farming land
and 28% of the livestock stock, revealed that 49% of the farms have
had at least one outbreak of bovine B. anthracis between 1977 and
2013 [15,16].
The anthrax vaccine currently used for adult bovines in
Argentina is based on live spores prepared from the attenuated,
capsule-deﬁcient B. anthracis Sterne strain (Weybridge no. 34F2).
The protective effect of a single dose in adult animals is assumed
to last for about 1 year [17], and therefore annual booster vaccina-
tions are recommended for livestock. This schedule can be per-
fectly coupled with the FMD vaccination program, provided that
FMDV titers are not reduced due to the simultaneous vaccination,
as this could lead to increase the risk of outbreaks in FMDV-free
regions.
There is little information in the literature regarding FMD vac-
cination efﬁcacy when applied together with other vaccines. In
fact, only two publications have addressed the simultaneous appli-
cation of FMD vaccine (FMD-vac) with other veterinary vaccines in
bovines. One study showed that immunization of young calves
immunized (by subcutaneous route) against FMD and against
infectious bovine rhinotracheitis/adenovirus/parainﬂuenza-3 (by
intranasal route) did not interfere with the serological response
against the FMD virus strains included in the vaccine [18].
Another study, however, showed interference between FMD-vac
and a vesicular stomatitis virus live vaccine [19]. Altogether, avail-
able data indicate that the simultaneous application of FMD vacci-
nes, particularly with live vaccines, needs to be evaluated.
In a ﬁrst attempt to address the possible interference of B.
anthracis live vaccine (ABV) with FMD-vac we studied the serolog-
ical response of cattle that received one dose of FMD-vac or
FMD-vac simultaneously with ABV. Due to the fact that all adult
animals in the region have vaccine-induced anti-FMDV antibodies,
and ABV is only applied in adult animals, we evaluated the serolog-
ical response to a booster FMD-vac dose (4th dose) applied alone or
together with the anthrax vaccine. Our data indicate that thesimultaneous application of these vaccines do not modify the sero-
logical response proﬁles to FMD booster vaccination. Moreover,
higher titers against FMDV were obtained at 25 days
post-vaccination (dpv) when both ABV and FMD-vac were applied,
mainly due to an increase in IgG2 antibody titers.
Materials and methods
Animals
Heifers used in this study were from the same farm and had
four previous FMD vaccinations, corresponding to FMD campaigns
of November 2011, March 2012, November 2012 and March 2013.
Thirty-two animals were selected from a herd of 120 heifers
according to the levels of antibodies against FMDV (O1/Campos
strain) measured by ELISA (LPBE, see below) a week before vacci-
nation. Animal handling, vaccination and serum sampling proce-
dures were previously approved by INTA’s Animal Welfare
Commission (protocol approval No. 025/2011).
Vaccines
Commercial vaccines were used in this study. The FMD vaccine,
referred here as ‘‘FMD-vac’’, was an oil-adjuvanted (water-in-oil)
vaccine containing inactivated FMDV from four strains: O1/
Campos, A24/Cruzeiro, A/Arg/01 and C3/Indaial and produced by
a local manufacturer. This vaccine was approved by SENASA
according to the current national regulations [6,20].
The bovine anthrax vaccine ‘‘PROVIDEAN CARBUNCLO’’
(Tecnovax SA, Buenos Aires, Argentina), here called ‘‘ABV’’, contains
non-encapsulated, non-virulent spores of B. anthracis F234 Sterne
strain with an antigen payload of 1.8  107 spores per dose.
Experimental design
The day of vaccination, 32 animals that had received three
previous vaccinations and showing LPBE titers against FMDV
O1/Campos ranging from 3.37 to 3.96, were selected from a herd
of 120 animals, and randomly distributed in two groups of 16 ani-
mals. One group received 2 mL of FMD-vac applied subcutaneously
in the left side of the neck (Group FMD-vac). The other remaining
16 animals received the same vaccine and also 2 mL of ABV (also
subcutaneously) in the right side of the neck (Group
FMD-vac + ABV). Serum samples (2 aliquots of 2 mL each per
animal) obtained at 0, 25, 55 and 90 dpv were stored at 20 C
for further serological assessments.
Liquid phase blocking ELISA (LPBE)
Total anti-FMDV O1/Campos and anti-FMDV A24/Cruzeiro anti-
body responses were assessed in serum samples by LPBE per-
formed as stated by the OIE Manual using a rabbit antiserum to
capture inactivated whole 140S viral particles, and a guinea-pig
antiserum as detector antibody, both of them strain-speciﬁc as
described before [21]. Antibody titers were expressed as the recip-
rocal Log10 of serum dilutions giving the 50% of the absorbance
recorded in the virus control wells without serum.
Single dilution avidity ELISA
Avidity assessment of speciﬁc antibodies was performed as
described before [22]. The Avidity Index (AI) was calculated as
the percentage of residual activity of the serum sample after a
20 min urea washing step, relative to that of untreated sample:
AI% = (OD sample with urea/OD sample without urea)  100.
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Isotype ELISAs were performed as reported before [21,22] using
HRP-conjugated antibodies anti IgG1 (1:750), IgG2 (1:750) and IgM
(1:500) (AbD Serotec, Oxford, UK). Serum samples were run in
twofold serial dilutions starting at 1:50. Titers were expressed as
Log10 of the dilution factor reaching the cut-off value OD = 0.2
[22].
Data analysis
The ‘‘expected protection percentage’’ (EPP) was used as a refer-
ence to protective vaccine-induced responses. The EPP relates anti-
body titers measured by LPBE at 60 dpv, with the percentages of
protection achieved for the same groups of animals after in vivo
challenge experiments performed at 90 dpv following the ‘‘protec-
tion against generalized foot infection’’ (PGP) test. LPBE titers cor-
responding to EPP values = 75% (EPP-75%) are 2.11 for the
O1/Campos strain [23,24] and 1.90 for A24/Cruzeiro strain [24].
Time-course titers obtained by LPBE, AI and IgG-subtype ELISAs
were plotted and results between the two experimental groups
were compared by ANOVA 2-factor repeated measures followed
by Bonferroni multiple comparisons test. Mann–Whitney test
was used when data from two groups were compared. The conﬁ-
dence interval was 95%. Statistical analyses were carried out using
GraphPad Prism v5.0 (GraphPad Software).Fig. 1. Kinetics of total antibody titers against O1/Campos (A) and A24/Cruzeiro (B)
measured by LPBE. Group FMD-vac (n = 16; black circles) correspond to bovines
that received one dose of a commercial tetravalent FMD vaccine. Animals from
group FMD-vac + ABV (n = 16; white circles) were simultaneously immunized with
FMD-vac and a commercial bovine anthrax vaccine. Mean titers standard errors
(SEM) are depicted. Vaccination is indicated with an arrow. A titer of 2.11 is
considered to be related to an EEPP 75% for O1/Campos strain. #Titers against O1/
Campos were signiﬁcantly higher in FMD-vac + ABV compared to FMD-vac at 25
dpv. &Titers against A24/Cruzeiro were signiﬁcantly higher in FMD-vac + ABV
compared to FMD-vac at 25 dpv. ⁄Titers are signiﬁcantly higher than those
measured at 0 dpv.Results
Total antibodies against FMDV
Thirty-two calves with LPBE titers (against FMDV O1/Campos
strain) ranging from 3.37 to 3.96 were randomly grouped to
receive either FMD-vac alone (mean LPBE titer at 0 dpv = 3.69;
range 3.37–3.94) or both FMD-vac and ABV (mean LPBE titer at
0 dpv = 3.68; range 3.39–3.96). Serum samples were obtained the
day of vaccination and at 25, 55 and 90 dpv and analyzed by
LPBE and avidity ELISA against two of the strains included in the
vaccine, O1/Campos and A24/Cruzeiro.
LPBE kinetics curves were similar between both groups, for both
tested strains (Fig. 1). Total antibody titers increased after vaccina-
tion in all the animals, and were maintained within high levels [23]
(P3.7) up to the end of the experiment. At 25 dpv, antibody titers
against O1/Campos where signiﬁcantly higher from those observed
at 0 dpv for the group immunized with FMD-vac + ABV, compared
to FMD-vac (Fig. 1). The increase in antibody titers at 25 dpv for ani-
mals immunized with FMD-vac alone compared to FMD-vac + ABV
was signiﬁcant for O1/Campos (p = 0.04) but marginally signiﬁcant
for A24/Cruzeiro (p = 0.052).
Avidity indexes kinetic curves were comparable for both groups
(Fig. 2). Interestingly, multi-vaccinated animals had lower level of
avidity against O1/Campos than against A24/Cruzeiro at 0 dpv.
Antibody avidity was boosted after vaccination, though differences
were not signiﬁcant. High AI levels were maintained thereafter
until the end of the experiment for both tested strains.
Isotype responses
We hypothesized that the higher titers observed for O1/Campos
strain at 25 dpv might be due to an increase in a particular isotype
titers, probably biased by the cytokine environment induced by the
live bacteria. To test this hypothesis, IgG1 and IgG2 titers against
O1/Campos were determined in serum samples from both experi-
mental groups obtained at 0, 25 and 90 dpv (Fig. 3). An increase in
IgG1 and IgG2 anti-FMDV serum titers were observed for allvaccinated animals against both virus strains. IgG1 titers and
kinetics were similar in both groups (Fig. 3A). However, IgG2 titers
were higher for those bovines immunized with FMD-vac + ABV
compared to FMD-vac alone at 25 dpv (Fig. 3C and D). At longer
time-points, however, no signiﬁcant differences were detected.Discussion
FMD has global consequences, costing an estimated USD $6–
$21 billion each year in prevention expenditures and agricultural
damage [2]. A signiﬁcant portion of this cost is shouldered by the
world’s poorest countries, which experience major economic
losses from trade restrictions. Argentina is free from the disease,
but situated in a territory under a constant threat of incursions
of the virus. Local sanitary authorities carry on an active compul-
sory vaccination program in large regions of the country, which
assures the maintenance of the FMD-free status granted by the
World Organization for Animal Health [25].
In this scenario, other disease control programs may also bene-
ﬁt from the complex logistics deployed for the FMD vaccination
campaigns, by the simultaneous application of their corresponding
vaccines. Argentina conducts such combined vaccination programs
for Brucellosis in 3–8 months-old calves [26] and recently a pilot
plan has been launched in certain sanitary districts of the country
for simultaneous vaccination against FMD and anthrax.
There is little information, however, on how the co-application
of FMD-vac and other vaccines may interfere with the immune
Fig. 2. Kinetics of the avidity index of antibodies against O1/Campos (A) and A/24
Cruzeiro (B) measured by ELISA in serum from animals immunized with one dose of
a commercial tetravalent FMD vaccine applied alone (FMD-vac, black circles) or
simultaneously with bovine anthrax vaccine (FMD-vac + ABV, white circles). Mean
values ± SEM were shown. Vaccination is indicated with an arrow. Values
AIP 24.5% are considered protective for an A strain.
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application of a tetravalent FMD vaccine and a bacterial live vac-
cine modify booster humoral responses against two of the strains
included in the FMD vaccine. The study was designed to evaluate
booster responses to match the practical approach applied in the
ﬁeld, as adult animals that should be immunized with the anthrax
vaccine would have already undergone at least three FMD ofﬁcial
vaccination campaigns.
FMD immune responses to vaccination are evaluated by
SENASA using LPBE, and there are published curves relating LPBE
titers with protection. An EPP of 75% has been estimated to corre-
spond to LPBE titers equal to 1.90 and 2.11 for A24/Cruzeiro and
O1/Campos strains, respectively [23,24]. The animals included in
this study presented antibody titers corresponding to EPP values
above 99% for both strains, at all-time points and regardless the
vaccination they received. The kinetics curves obtained with a
booster FMD vaccination are similar to those measured before,
using also FMD commercial vaccines [22]. These results indicate
that the simultaneous vaccination with FMD-vac and ABV did not
modify the levels of total circulating anti-FMDV antibodies induced
by FMD-vac, for the two tested strains.
Avidity of speciﬁc antibodies has also been associated to protec-
tion. Although explored as an indirect assessment of
cross-protection, avidity of antibodies is related to their ability to
neutralize the virus and probably to favor its clearance in vivo. At
the beginning of the experiment, avidity levels were over the
24.5% AI threshold established before for A strains [22,27].
Avidity indexes were lower at 0 dpv for O1/Campos strain, com-
pared to A24/Cruzeiro. This might probably be related to the higher
structural stability of A24/Cruzeiro 140S particles compared to
O1/Campos, which may impact on the induced immune responses
[28]. However, as no AI curves have been validated yet for
O1/Campos strain, we cannot rule out the possibility of a technical
artifact in this assessment. Overall, antibody avidity was equally
boosted after applying FMD-vac or FMD-vac + ABV, producing0
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42 M. Trotta et al. / Trials in Vaccinology 4 (2015) 38–42similar kinetics curve, also comparable to AI% responses measured
before for booster vaccination. This is another argument to support
the lack of interference of the simultaneous vaccination with
FMD-vac and ABV.
We observed a signiﬁcant increase in total antibody levels at
25 dpv, for the O1/Campos strain, when the vaccines were
co-administered compared to the FMD-vac applied alone. We also
showed that this increase may be explained by the presence of
higher IgG2 titers. There is no information in the literature about
the cytokine milieu provoked by anthrax Sterne-strain vaccine in
cattle, which may explain this isotype-proﬁling. However, there
are reports supporting the induction of pro-inﬂammatory cytoki-
nes during murine anthrax [29] and by anthrax lethal toxin in
human endothelium [30], meaning that this bacterium can pro-
mote a Th1-biased pro-inﬂammatory environment. Is it possible
that the cytokine environment generated by the anthrax vaccine
promoted an expansion of Th1 clones which in term helped to
induce the proliferation of IgG2-producing B cells.
Altogether, the data provided in this study demonstrate that the
Sterne-strain live anthrax vaccine can be administered simultane-
ously with an oil-based tetravalent FMD vaccine in adult cattle,
producing no impact in the humoral responses against FMDV boos-
ter responses. It will be also interesting to evaluate the impact of
primary simultaneous immunization of both vaccines and the
immune responses against anthrax. This is the ﬁrst study on the
FMD responses elicited in cattle simultaneously immunized with
FMD and anthrax vaccines. The information provided here can be
particularly useful for endemic regions with compulsory FMD vac-
cine programs.
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